C

Cansortium Inc
CNSX:TIUM.U

Watchlist Manager
Cansortium Inc
CNSX:TIUM.U
Watchlist
Price: 0.055 CAD Market Closed
Market Cap: CA$33.7m

Relative Value

There is not enough data to reliably calculate the relative value of TIUM.U.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TIUM.U Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

TIUM.U Competitors Multiples
Cansortium Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Cansortium Inc
CNSX:TIUM.U
33.7m CAD 0.2 -1.5 1.4 2.5
US
Eli Lilly and Co
NYSE:LLY
985.1B USD 16.6 53.5 35.9 38.5
US
Johnson & Johnson
NYSE:JNJ
554.2B USD 5.9 20.7 14.4 17.7
CH
Roche Holding AG
SIX:ROG
281B CHF 4.6 29.7 12.6 14.7
UK
AstraZeneca PLC
LSE:AZN
217.8B GBP 5.1 31.4 20.4 29.8
CH
Novartis AG
SIX:NOVN
224.3B CHF 5.1 19.8 15.8 20.4
US
Merck & Co Inc
NYSE:MRK
281.3B USD 4.4 14.8 10.4 12.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.7 10.9 12.7
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
150.9B USD 2.4 15.4 7.7 10.6
FR
Sanofi SA
PAR:SAN
97.3B EUR 1.7 8.2 7.7 7.7
P/E Multiple
Earnings Growth PEG
US
C
Cansortium Inc
CNSX:TIUM.U
Average P/E: 23.2
Negative Multiple: -1.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.5
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.7
6%
3.4
CH
Roche Holding AG
SIX:ROG
29.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
38%
0.8
CH
Novartis AG
SIX:NOVN
19.8
17%
1.2
US
Merck & Co Inc
NYSE:MRK
14.8
14%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
2%
7.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.4
27%
0.6
FR
Sanofi SA
PAR:SAN
8.2
1%
8.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
C
Cansortium Inc
CNSX:TIUM.U
Average EV/EBITDA: 43.8
1.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.9
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.4
2%
7.2
CH
Roche Holding AG
SIX:ROG
12.6
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
20.4
10%
2
CH
Novartis AG
SIX:NOVN
15.8
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10.4
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
C
Cansortium Inc
CNSX:TIUM.U
Average EV/EBIT: 93.8
2.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.5
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.7
6%
2.9
CH
Roche Holding AG
SIX:ROG
14.7
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
29.8
23%
1.3
CH
Novartis AG
SIX:NOVN
20.4
12%
1.7
US
Merck & Co Inc
NYSE:MRK
12.4
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.6
7%
1.5
FR
Sanofi SA
PAR:SAN
7.7
6%
1.3